Log in

Clearside Biomedical Stock Price, Forecast & Analysis (NASDAQ:CLSD)

$1.01
-0.06 (-5.61 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$1.01
Now: $1.01
$1.07
50-Day Range
$0.60
MA: $0.92
$1.33
52-Week Range
$0.56
Now: $1.01
$1.92
Volume402,700 shs
Average Volume860,840 shs
Market Capitalization$41.56 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.34
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Book Value$0.24 per share

Profitability

Net Income$-82,820,000.00
Net Margins-18,893.49%

Miscellaneous

Employees50
Market Cap$41.56 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.


Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical Inc (NASDAQ:CLSD) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.01. The company earned $0.14 million during the quarter, compared to analysts' expectations of $0.05 million. Clearside Biomedical had a negative return on equity of 316.25% and a negative net margin of 18,893.49%. View Clearside Biomedical's Earnings History.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Clearside Biomedical.

What price target have analysts set for CLSD?

5 analysts have issued 1 year target prices for Clearside Biomedical's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Clearside Biomedical's stock price to reach $3.00 in the next year. This suggests a possible upside of 197.0% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.

What is the consensus analysts' recommendation for Clearside Biomedical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clearside Biomedical.

What are Wall Street analysts saying about Clearside Biomedical stock?

Here are some recent quotes from research analysts about Clearside Biomedical stock:
  • 1. According to Zacks Investment Research, "Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. " (11/11/2019)
  • 2. Wedbush analysts commented, "Our $69 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate of $7.49 to arrive at our price target. We use a 20% discount rate for the pipeline as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development." (8/6/2019)

Has Clearside Biomedical been receiving favorable news coverage?

Press coverage about CLSD stock has trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clearside Biomedical earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Clearside Biomedical.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 663,000 shares, a decrease of 51.3% from the September 30th total of 1,360,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is currently 0.6 days. Approximately 2.2% of the shares of the company are short sold. View Clearside Biomedical's Current Options Chain.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the folowing people:
  • Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
  • Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
  • Mr. Rick McElheny, VP of Corp. Devel.

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.01.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $41.56 million and generates $30,000.00 in revenue each year. The company earns $-82,820,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.View Additional Information About Clearside Biomedical.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is http://www.clearsidebio.com/.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: Day Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel